NCT03409614 2026-05-18Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung CancerRegeneron PharmaceuticalsPhase 3 Completed789 enrolled 32 charts 1 FDA